As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

During the time period 2020 to 2023, approximately 1 in 5 youth and 1 in 3 adults with type 1 diabetes and severe obesity ...

The rapid increase in the use of glucagon-like peptide-1 receptor agonists for weight loss, diabetes management and ...

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

Pooled annual prevalence of GLP-1 RA use was 0.1 percent from 2018 to 2021 and increased to 0.4 percent by 2022.

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper supervision, and a protein-rich diet, the results of a new study suggest.

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.